Muna Therapeutics Aps has patented new dihydropyrrolopyrimidinone compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of osteoporosis, rheumatoid arthritis, systemic lupus erythematosus, type 2 diabetes, obesity, metabolic dysfunction-associated steatotic liver disease (MASLD; NAFLD), neurodegeneration and inflammatory bowel disease, among others.
Deep Apple Therapeutics Inc. has divulged new alkylphenyl substituted compounds acting as gastric inhibitory polypeptide receptor (GIPR) antagonists potentially useful for the treatment of obesity and type 2 diabetes.
Zhongshan Laibo Ruichen Biomedicine Co. Ltd. has patented new polypeptides and their drug conjugates potentially useful for the treatment of osteoporosis.
Protuoso Biosciences has announced the close of an oversubscribed $9.5 million seed financing round, the proceeds of which will be used to advance its multifunctional protein engineering platform and broad pipeline across cardiometabolic, oncology and autoimmune diseases.
Merck Sharp & Dohme LLC (MSD) has disclosed new glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of obesity and type 2 diabetes.
Kallyope Inc. has identified new gastrin-releasing peptide receptor (GRPR) agonists potentially useful for the treatment of gastrointestinal disorders and obesity.
Newcelx Ltd. has submitted a pre-IND briefing package to the U.S. FDA to support a proposed first-in-human trial of NCEL-101 in combination with tegoprubart, an investigational anti-CD40L monoclonal antibody being developed by Eledon Pharmaceuticals Inc.
Fabry disease is a lysosomal storage disease tied to the X chromosome and caused by pathogenic variants in the GLA gene encoding galactosidase A. It is characterized by progressive accumulation of galactosidase A substrates, including Gb3 and lyso-Gb3, mainly in the kidney, heart and nervous system.
Selection Therapeutics GmbH has discovered new potassium voltage-gated channel subfamily A member 3 (KCNA3; Kv1.3) blockers potentially useful for the treatment of autoimmune disease, diabetes, obesity, periodontitis and transplant rejection.
RSS
